FDA Drug Recalls

Recalls / Class I

Class ID-0938-2023

Class I— FDA's most serious classification, issued when there is a reasonable probability that use of or exposure to the drug will cause serious adverse health consequences or death.

Product

Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 Metered Inhalation, net content 6.7 g canister packaged in a box, Rx only, Manufactured by: Cipla Ltd, Indore SE Z, Pithampur, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ, 07059, NDC 69097-142-60

Brand name
Albuterol Sulfate
Generic name
Albuterol Sulfate
Active ingredient
Albuterol Sulfate
Route
Respiratory (inhalation)
NDC
69097-142
FDA application
ANDA209959
Affected lot / code info
Lot # IB20045, IB20055, IB20056, IB20057, IB20059, IB20072, Exp Nov. 30, 2023

Why it was recalled

Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).

Recalling firm

Firm
Cipla USA, Inc.
Manufacturer
Cipla USA Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
10 Independence Blvd, N/A, Warren, New Jersey 07059-2730

Distribution

Quantity
278,538 canisters
Distribution pattern
Nationwide in the US

Timeline

Recall initiated
2023-06-27
FDA classified
2023-07-21
Posted by FDA
2023-07-19
Terminated
2025-03-06
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0938-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.